ABSTRACT. The renin-angiotensin-aldosterone system plays a key role in regulating blood pressure by maintaining vascular tone and the water/sodium balance. Many antihypertensive drugs target the reninangiotensin-aldosterone system, but the effect differs considerably among hypertensive patients. We investigated whether genetic variants of the angiotensin II type 1 receptor are associated with blood pressure response to angiotensin II receptor blockers in hypertensive Chinese patients. After a 2-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy with 80 mg/day telmisartan and then were followed up for 8 weeks. The 1166A/C, 573T/C, -810A/T, and -521C/T polymorphisms of the AT1R gene were determined through PCR and RFLP analysis. The relationship between these polymorphisms and changes in blood pressure was observed and evaluated after 8 weeks of treatment. 
INTRODUCTION
Hypertension affects approximately one billion individuals worldwide and is a major risk factor for cardiovascular and cerebrovascular disease (Chobanian et al., 2003) . Successful control of blood pressure could reduce the prevalence and incidence of myocardial infarction, stroke, heart failure, and renal disease. However, individual response to antihypertensive therapy is highly variable. Past efforts to identify responders to therapy include phenotypic (age, race) (Preston et al., 1998) and biochemical (renin profile, insulin sensitivity) factors (Laragh et al., 1988; Lind et al., 1995) , but none of them revealed the value of extensive clinical utilization. Recent studies indicate that genetic variations may influence the clinical response to pharmacological treatment (Sciarrone et al., 2003; Filigheddu et al., 2004; Yu et al., 2006; Su et al., 2007) .
The renin-angiotensin-aldosterone system is implicated in the pathogenesis of hypertension, cardiac hypertrophy and coronary heart disease. The major biologically active product of the renin-angiotensin system is angiotensin II, it plays important roles in normal physiology and in the progression of cardiac and renal diseases. Most of the effects of angiotensin II are mainly mediated by the angiotensin II type 1 receptor (AT1R), including vascular contraction, pressor responses, renal tubular sodium transport, and aldosterone secretion (Timmermans et al., 1993) . The AT1R gene has a length of over 55 kb and consists of 5 exons and 4 introns. Bonnardeaux et al. (1994) screened exon 5 and the 3ꞌ-untranslated region (UTR) for mutations in 50 hypertensive subjects and identified several frequent polymorphisms, one of which, either an adenine (A) or a cytosine (C) base (A/C transversion) at nucleotide position +1166 in the 3ꞌ-URT, was found to be associated with hypertension (Kikuya et al., 2003) . Subsequent studies have examined the relation to arterial hypertension (Benetos et al., 1996) , aortic stiffness (Nakauchi et al., 1996) , myocardial infarction (Takami et al., 1998) , hypertension-induced hypertrophy (Chapman et al., 2001) , and carotid intimal-medial thickening (Miller et al., 1999) . However, to date, whether or not there is a correlation between genetic variants of AT1R and effects of antihypertensive drugs is really interesting but still unclear.
Our study aimed at evaluating the impact of AT1R gene polymorphisms on the antihypertensive response in hypertensive patients receiving the angiotensin II receptor blocker telmisartan. Among the 4 variants, including 1166A/C and 573T/C in exon 5 as well as -810A/ T and -521C/T in the promoter region, we found that in Chinese patients the -521CC genotype is the only one related to higher sensitivity to telmisartan treatment.
MATERIAL AND METHODS

Study subjects
In this study, both male and female Chinese Han patients who met the following criteria were included: 18 to 80 years old; history of essential hypertension; diastolic blood pressure (DBP) from 90 to 109 mmHg; systolic blood pressure (SBP) from 140 to 179 mmHg. The exclusion criteria were as follows: secondary hypertension, congestive heart failure, cerebrovascular accident, myocardial infarction within the past 3 months; a documented history of unstable angina pectoris within the past 3 months; any clinically important abnormal laboratory findings, such as alanine aminotransferase (ALT) or creatinine level twice the upper limit of normal; pregnancy or lactation in women. The appropriate Ethics Committees approved this study. All of the participating patients gave informed consent before any study procedures.
Study design
Blood pressure (BP) was measured by a well-trained doctor or nurse using a mercury sphygmomanometer after the patient had rested for at least 10 min in a seated position and was determined as the mean of 3 measurements taken 2 min apart. A total of 164 patients were recruited with essential hypertension in our study. All antihypertensive agents were withdrawn before the start of a 2-week placebo period. At the end of the placebo period, 11 patients were excluded and a total of 153 qualified patients were given telmisartan, 80 mg orally, once daily for 8 weeks. Five patients withdrew from the study because of failing to follow-up. Thus, 148 patients completed the 8-week trial, and their data were used for the present study. Blood was collected from all patients for genotype analysis.
Definition of study variables
Baseline information on the following variables was included in the analysis: gender, age, body mass index (BMI, kg/m 2 ), BP, heart rate. Laboratory variables included the serum levels of ALT, creatinine, glucose, uric acid, total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL), sodium, potassium and angiotensin II.
Detection of AT1R gene polymorphisms
Genomic DNA was isolated from peripheral leukocytes separated from red blood cells according to the procedure of Tilzer et al. (1989) . The AT1R polymorphisms were determined by PCR/RFLP. A 20-μL PCR reaction mixture contained 10X PCR buffer, 1.5 mM MgCl 2 , 0.1 mM of each dNTP, 0.5 μM of each primer, 1 U Taq enzyme (Takara), and 100 ng genomic DNA. The primers for the 4 polymorphic sites are shown in Table 1 . The annealing temperatures of the 4 variant sites of PCR were set up differently as 1166 at 56°C, 573 at 50°C, -810 at 58°C, and -521 at 59°C. After PCR amplification, restriction enzymes DdeI, Mn1I, AluI, and SspI (New England Biochemicals) were respectively applied to digest the PCR products for the 1166, 573, -810, and -521 sites. The digested PCR products were then loaded on a 3% ethidium bromide-stained agarose gel to identify the product sizes.
Impact of the AT1R gene on ARB therapeutic efficacy
Statistical analysis
Data are reported as means ± standard deviation (SD). The c 2 test was used to evaluate categorical variables and test for Hardy-Weinberg equilibrium (HWE) of polymorphisms. Differences in biochemical parameters and BP were assessed using a paired t-test. Linear regression modeling was used to determine the correlation of BP response with genotypes, following normalization with pretreatment BP, age, gender, BMI, blood glucose, TC, TG, HDL, and LDL. The SPSS 11.5 software was applied for statistical analysis. A two-tailed P value less than 0.05 was considered to be significant.
RESULTS
Characteristics of the study subject
Data from the 148 patients were analyzed in this study. All patients had mildto-moderate hypertension. The basic characteristics of patients are presented in Table  2 . After a 8-week treatment with telmisartan, both SBP and DBP were remarkably decreased (P < 0.001). The serum angiotensin II level was obviously increased at the end of the 8-week treatment (P < 0.001). No significant differences were observed for the other parameters.
Genotype and antihypertensive response to telmisartan
Genotype and allele distributions of the study population are summarized in Table 3 . Genotype and allele frequencies of each polymorphism in the study population were in HWE (P > 0.05). The changes in BP response to antihypertensive treatment in relation to genotypes of AT1R gene polymorphisms are shown in Table 4 . Five subjects carrying the homozygous -521T allele was found, so CT and TT genotypes were used in combination for analyses. We did not find any association of AT1R 1166A/C, 573T/C, and -810A/T polymorphisms with SBP or DBP response to telmisartan. Surprisingly, linear regression analysis indicated that only AT1R -521C/T was associated with DBP response to telmisartan, after correction with covariates, including pretreatment DBP, age, gender, BMI, blood glucose, TC, TG, HDL, and LDL (P = 0.039). AT1R -521C/T accounted for 17.7% of interindividual variation in the DBP response to telmisartan. The patients carrying the -521CC genotype showed a greater reduction in DBP than those carrying the T allele (CT+TT) (Figure 1 ).
Polymorphism site
Primer sequence Restriction enzyme 1166 Forward: 5ꞌ-TCA TCC ACC AAG AAG CCT-3ꞌ DdeI Reverse: 5ꞌ-TCC TGT TGC TCC TCT AAC G-3ꞌ 573
Forward: 5ꞌ-CTT GTA GCC AAA GTC ACC T-3ꞌ Mn1I Reverse: 5ꞌ-CGT GTC CAC AAT ATC TGC-3ꞌ -810
Forward: 5ꞌ-CCA GAT AAA GAC ATC ACG AGA C-3ꞌ AluI Reverse: 5ꞌ-ACA GTC ACC CTA CTC ACC TAG C-3ꞌ -521
Forward: 5ꞌ-CGA ACT TTG GTA ATA CAG TTG TGG-3ꞌ SspI Reverse: 5ꞌ-GAG TTG GGA GAT CAT CCT TAC TC-3ꞌ Table 2 . Changes of patient characteristics and blood pressure response to the treatment.
Data are reported as means ± SD. The P value was calculated by the paired-samples t-test. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; ALT = alanine aminotransferase; AST = aspartate aminotransferase; Cr = creatinine; BUN = blood urea nitrogen; UA = uric acid; Glu = glucose; TC = total cholesterol; TG = triglyceride; LDL = low-density lipoprotein; HDL = high-density lipoprotein; Na + = sodium ion; K + = potassium ion; Cl -= chloride ion; Ang II = angiotensin II. Table 3 . Genotype and allele frequencies of the 1166A/C, 573T/C, -810A/T, and -521C/T polymorphisms of the AT1R gene in the study population. Table 4 . SNPs of the AT1R gene in linear regression and blood pressure (BP) response to antihypertensive drugs.
Four SNPs were first considered by themselves (alone) as a predictor of the BP response, then after adjustment for the concomitant variables including pretreatment BP, age, gender, BMI, glucose, TG, TC, HDL, and LDL (after covariates). Standardized β is the standardized regression coefficient; R 2 is the percentage of interindividual variation in BP response explained by predictors in the model. 
DISCUSSION
AT1R -521C/T is localized in the promoter region. It is unclear whether hypertension or antihypertensive drug effect is associated with polymorphisms in the promoter of the AT1R gene. Erdamann et al. (1999) characterized 9 sequence variants located in the functional promoter region of the AT1R gene, which may have the potential to influence AT1R gene expression. Moreover, 7 of these variants were found to be completely linked, such that the analysis of 3 single nucleotide polymorphism (SNPs) should provide information for all possible haplotypes. The ECTIM study indicated that the -810A/T polymorphism may be associated with the risk of myocardial infarction in males (Poirier et al., 1998) . Moreover, among 6 SNPs discovered in the promoter region of the AT1R gene, Jin et al. (2003) found that the -810A/T is almost in complete linkage disequilibrium with 4 other SNPs (-713G/T, -214A/C, -213G/C, and -153A/G) and the -810A/T polymorphism is a genetic risk factor for essential hypertension complicated with coronary heart disease. Until now, little is known about the association between polymorphisms in the promoter of the AT1R gene and blood pressure response to antihypertensive treatment. We genotyped the 2 polymorphic sites -810A/T and -521C/T, which do not exist in linkage disequilibrium, and found AT1R -521C/T associated with blood pressure responses. In this study, we revealed that the AT1R -521C/T polymorphism was associated with BP response to antihypertensive drug. After a 8-week telmisartan treatment, patients carrying the -521CC genotype showed a greater reduction in DBP than those carrying the T allele. The association remained after adjustment for multiple comparisons as well as for potential confounding factors including baseline BP. To our knowledge, our study is the first to prove that the -521C/T variation is associated with an antihypertensive effect.
At present, the 1166A/C polymorphism is the best evaluated. This polymorphism is located in an untranslated region of the gene, but may be in linkage disequilibrium with a functional variant, which could affect the regulation of the gene in response to Ang II. Miller et al. (1999) hypothesized that renal and systemic angiotensin II activity would be augmented in subjects with the C allele of the AT1R gene +1166A/C polymorphism, and tested this hypoth-esis by comparing hemodynamic and humoral responses to AT1R blockade with losartan and with low-dose suppressor infusion of angiotensin II (Guo et al., 1994) . In this study, losartan increased the glomerular filtration rate and decreased mean arterial blood pressure in subjects with the C allele. Kurland et al. (2001) did not show relationships between AGT M235T or AT1R A1166C polymorphism and response to treatment for 3 months with irbesartan or atenolol, whereas the ACE I/D genotype predicted the blood-lowering response to these antihypertensive therapies. In our study, there was a tendency for a greater SBP reduction in patients carrying the C allele compared with those carrying the T allele after treatment, but it did not reach statistical significance (data not shown). One possible explanation for the result is that relatively small numbers of subjects were included in this study. There were also no significant differences between the 2 genotype groups in angiotensin II level before and after treatment.
Another SNP also has been described in which there is either a thymine (T) or a cytosine (C) base (C/T transversion) in nucleotide position 573 in exon 5. The presence of the T573C polymorphism of the AT1R gene has been associated with hypertension and diabetes (Doria et al., 1997; Chaves et al., 2001) . Chaves et al. (2001) found that the T573C polymorphism may be a genetic protective factor for urinary albumin excretion in a population of essential hypertensive patients. However, Redon et al. (2005) found that neither blood pressure response nor the rate of urinary albumin excretion had any relationship with the presence of the T573C polymorphism while on telmisartan therapy. Our present results are consistent with the above findings.
The limitation of our study is the focus on only a lowering of BP. We recognize that for long-term clinical outcomes (coronary heart disease, stroke, chronic kidney disease) it may be more important to elucidate individual gene-drug interactions on end points in a clinical setting. Outcome-based research may result in more effective BP control and a lower incidence of hypertension-related morbidity and mortality (Psaty et al., 2002; Bis et al., 2003) . We plan to use this approach to study the outcomes and antihypertensive treatment in the future.
